Design, execution, and preliminary biomarker results from paired tumor biopsy cohorts of the AZD9291 AURA trial

Joseph Geradts , Fiona Blackhall , Karthick Vishwanathan , Kenneth Thress
Journal of Thoracic Oncology

1
2015
Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

J Tanizaki , I Okamoto , K Takezawa , K Sakai
British Journal of Cancer 106 ( 4) 763 -767

42
2012
A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples.

Martin Sattler , Christoph Walz , Brian J. Crowley , Eva Lengfelder
Blood 107 ( 3) 1237 -1238

18
2006
Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR

Jin Li , Lilin Wang , Pasi A Jänne , G Mike Makrigiorgos
Clinical Chemistry 55 ( 4) 748 -756

60
2009
Macrocyclization of quinazoline-based EGFR inhibitors leads to exclusive mutant selectivity for EGFR L858R and Del19

Jennifer A Amrhein , Tyler S Beyett , William W Feng , Andreas Krämer
Journal of Medicinal Chemistry 65 ( 23) 15679 -15697

2022
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A Engelman , Kreshnik Zejnullahu , Tetsuya Mitsudomi , Youngchul Song
Yearbook of Oncology 2008 201

5,154
2008
Phase II clinical trial of chemotherapy-naive patients≥ 70 years of age treated with erlotinib for advanced non–small-cell lung cancer

David M Jackman , Beow Y Yeap , Neal I Lindeman , Panos Fidias
Journal of Clinical Oncology 25 ( 7) 760 -766

428
2007
Epidermal growth factor receptor mutation testing in the care of lung cancer patients

Lecia V Sequist , Victoria A Joshi , Pasi A Jänne , Daphne W Bell
Clinical cancer research 12 ( 14) 4403s -4408s

99
2006
Abstract A177: Cetuximab resistance associated with dimerization‐independence of oncogenic EGFR mutants

Jeonghee Cho , Liang Chen , Naveen Sangji , Jinyan Du
Molecular Cancer Therapeutics 8 ( 12_Supplement) A177 -A177

1
2009
65
2006
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma

Pasi A Jänne , George R Simon , Corey J Langer , Robert N Taub
Journal of clinical oncology 26 ( 9) 1465 -1471

56
2008
Gefitinib First or Gefitinib Second: Is Timing Everything in the Treatment of EGFR Mutant Non–Small Cell Lung Cancer?

Pasi A Jänne
American journal of respiratory and critical care medicine 178 ( 8) 783 -785

2
2008
ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases

Zhengnian Li , Wenchao Lu , Tyler S Beyett , Scott B Ficarro
Journal of Medicinal Chemistry

1
2024
Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality

Zhengnian Li , Jie Jiang , Scott B Ficarro , Tyler S Beyett
ACS Central Science

2024
Characterization of ALK splicing isoforms in EML4-ALK-translocated lung cancer.

Lorena F Pontes , Hiroyuki Yasuda , Pasi A Jänne , Daniel B Costa
Cancer Research 73 ( 8_Supplement) 1196 -1196

2013
Secondary mutations in ALK and resistance to ALK kinase inhibitors

Takaaki Sasaki , Katsuhiro Okuda , Wei Zheng , James Butrynski
Cancer Research 71 ( 8_Supplement) 1541 -1541

2011
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Thomas J Lynch , Alex A Adjei , Paul A Bunn Jr , Tim G Eisen
Clinical Cancer Research 12 ( 14) 4365s -4371s

41
2006